ArticleAmerican journal of translational research2024
Efficacies of different postoperative radiotherapy techniques in patients with N2 non-small cell lung cancer: a meta-analysis.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith clinical trials on the use of different modern precise radiotherapy techniques in the setting of postoperative radiotherapy (PORT) in N2 non-small cell lung cancer (NSCLC) accumulating, an updated meta-analysis was performed.
methodsA literature search identified studies that investigated PORT versus non-PORT in N2 NSCLC patients. Overall survival (OS) and locoregional recurrence (LR) were employed. The hazard ratio (HR) and relative risk (RR) with 95% confidence interval (CI) were analyzed.
resultsOverall, 33 studies comprised 8653 patients in the PORT group and 12398 in the non-PORT group. The HR for OS was 0.95 [95% CI: 0.91-0.98, P: 0.0009]. HRs of studies employing conventional radiotherapy, 3-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) were 0.90 [95% CI: 0.78-1.04, P: 0.16], 0.82 [95% CI: 0.72-0.93, P: 0.002] and 0.77 [95% CI: 0.64-0.91, P: 0.003], respectively. All HRs favor the PORT group. The RR for LR was 0.56 [95% CI: 0.49-0.65, P<0.00001]. RRs of studies employing conventional radiotherapy, 3D-CRT and IMRT were 0.61 [95% CI: 0.50-0.75, P<0.00001], 0.58 [95% CI: 0.46-0.72, P<0.00001] and 0.58 [95% CI: 0.45-0.73, P<0.00001], respectively.
conclusionPORT using 3D-CRT or IMRT benefits patients with N2 NSCLC in terms of LR and OS. PORT using conventional radiotherapy significantly decreases LR while it does not significantly increase OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.